JP7381190B2 - Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 - Google Patents

Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 Download PDF

Info

Publication number
JP7381190B2
JP7381190B2 JP2017534192A JP2017534192A JP7381190B2 JP 7381190 B2 JP7381190 B2 JP 7381190B2 JP 2017534192 A JP2017534192 A JP 2017534192A JP 2017534192 A JP2017534192 A JP 2017534192A JP 7381190 B2 JP7381190 B2 JP 7381190B2
Authority
JP
Japan
Prior art keywords
alkyl
amino
alkoxy
hydroxy
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017534192A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500354A (ja
Inventor
ペインター，ジョージ・アール
ガスリー，デイビッド・ビー
ブルームリング，グレゴリー・アール
ナチュス，マイケル・ジー
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56151433&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7381190(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2018500354A publication Critical patent/JP2018500354A/ja
Priority to JP2021204082A priority Critical patent/JP2022058363A/ja
Priority to JP2023118848A priority patent/JP2023153865A/ja
Application granted granted Critical
Publication of JP7381190B2 publication Critical patent/JP7381190B2/ja
Priority to JP2025030269A priority patent/JP2025098020A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/11—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids containing cyclic phosphate
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2017534192A 2014-12-26 2015-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途 Active JP7381190B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021204082A JP2022058363A (ja) 2014-12-26 2021-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2023118848A JP2023153865A (ja) 2014-12-26 2023-07-21 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2025030269A JP2025098020A (ja) 2014-12-26 2025-02-27 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462096915P 2014-12-26 2014-12-26
US62/096,915 2014-12-26
US201562201140P 2015-08-05 2015-08-05
US62/201,140 2015-08-05
PCT/US2015/066144 WO2016106050A1 (en) 2014-12-26 2015-12-16 N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2021204082A Division JP2022058363A (ja) 2014-12-26 2021-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2023118848A Division JP2023153865A (ja) 2014-12-26 2023-07-21 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Publications (2)

Publication Number Publication Date
JP2018500354A JP2018500354A (ja) 2018-01-11
JP7381190B2 true JP7381190B2 (ja) 2023-11-15

Family

ID=56151433

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017534192A Active JP7381190B2 (ja) 2014-12-26 2015-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2021204082A Pending JP2022058363A (ja) 2014-12-26 2021-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2023118848A Withdrawn JP2023153865A (ja) 2014-12-26 2023-07-21 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2025030269A Pending JP2025098020A (ja) 2014-12-26 2025-02-27 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021204082A Pending JP2022058363A (ja) 2014-12-26 2021-12-16 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2023118848A Withdrawn JP2023153865A (ja) 2014-12-26 2023-07-21 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP2025030269A Pending JP2025098020A (ja) 2014-12-26 2025-02-27 Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Country Status (23)

Country Link
US (3) US20190022116A1 (https=)
EP (2) EP3939985B1 (https=)
JP (4) JP7381190B2 (https=)
KR (2) KR20170123308A (https=)
CN (2) CN107427529A (https=)
AU (3) AU2015370004B2 (https=)
BR (1) BR112017013858A2 (https=)
CA (1) CA2972259A1 (https=)
CY (1) CY1124663T1 (https=)
DK (1) DK3236972T3 (https=)
EA (1) EA201791460A1 (https=)
ES (1) ES2892123T3 (https=)
HR (1) HRP20211456T1 (https=)
HU (1) HUE056470T2 (https=)
IL (3) IL296496B2 (https=)
LT (1) LT3236972T (https=)
PL (1) PL3236972T3 (https=)
PT (1) PT3236972T (https=)
RS (1) RS62434B1 (https=)
SG (2) SG11201705069YA (https=)
SI (1) SI3236972T1 (https=)
SM (1) SMT202100592T1 (https=)
WO (1) WO2016106050A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023153865A (ja) * 2014-12-26 2023-10-18 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE059718T2 (hu) 2016-09-02 2022-12-28 Dicerna Pharmaceuticals Inc 4'-foszfát analógok és azokat tartalmazó oligonukleotidok
EP3556764A4 (en) * 2016-12-16 2021-01-06 Gifu University NUCLEOSIDE DERIVATIVE AND USE FOR IT
JP7173467B2 (ja) 2017-10-31 2022-11-16 ヤマサ醤油株式会社 ヌクレオシド誘導体及びその利用
GB201720279D0 (en) 2017-12-05 2018-01-17 Nucana Biomed Ltd Anticancer compounds
PT3706762T (pt) * 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
CN108586294A (zh) * 2018-05-29 2018-09-28 王若锴 一种脲类衍生物及其在防治炎症中的应用
KR102783030B1 (ko) * 2019-02-01 2025-03-18 재단법인 경기도경제과학진흥원 중동호흡기증후군 치료 또는 예방용 약학 조성물
CN112390838A (zh) * 2019-08-14 2021-02-23 斯微(上海)生物科技有限公司 一种改性核苷及其合成方法
WO2021159044A1 (en) * 2020-02-07 2021-08-12 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN111548384B (zh) * 2020-03-29 2021-04-27 常州安蒂卫生物科技有限公司 用于抗病毒治疗的被取代的n4-羟基胞苷衍生物及其前药
CA3173931A1 (en) * 2020-04-03 2021-10-07 Felix Frueh Viral entry inhibitors and rna polymerase inhibitors
US11642372B2 (en) 2020-05-01 2023-05-09 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12042514B2 (en) 2020-05-01 2024-07-23 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US11826382B2 (en) 2020-05-01 2023-11-28 Tygrus, LLC Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
US12173029B2 (en) * 2020-07-24 2024-12-24 The Regents Of The University Of California Antiviral prodrugs, pharmaceutical formulations, and methods
US11702440B2 (en) * 2020-12-10 2023-07-18 Optimus Drugs Private Limited Pharmaceutical polymorphs of Molnupiravir
CN114621229B (zh) * 2020-12-11 2024-07-02 嘉兴金派特生物科技有限公司 治疗或预防猫传染性腹膜炎的化合物或组合物
CN112279877B (zh) * 2020-12-15 2021-08-06 南京颐媛生物医学研究院有限公司 一种核苷磷酸酯及其合成方法
KR20230121622A (ko) * 2020-12-18 2023-08-18 머크 샤프 앤드 돔 엘엘씨 항바이러스 뉴클레오시드의 합성
CN112608357B (zh) * 2020-12-21 2022-12-09 杭州科巢生物科技有限公司 一种抗病毒药物Molnupiravir的制备方法
CN112939981B (zh) * 2021-01-19 2022-08-26 嘉兴金派特生物科技有限公司 核苷化合物、药学上可接受的盐、组合物及其应用
US20240100018A1 (en) * 2021-01-22 2024-03-28 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Compounds for the treatment of a disease or disorder, methods for identifying said compounds
MX2023011870A (es) * 2021-04-09 2023-12-07 Univ Emory Análogos de nucleósidos y de nucleótidos como agentes antivirales para coronavirus y otros virus.
US11407779B1 (en) * 2021-04-23 2022-08-09 Divi's Laboratories Ltd. Process for the preparation of molnupiravir
US20240239832A1 (en) * 2021-05-06 2024-07-18 Council Of Scientific And Industrial Research A process for the preparation of n4-hydroxycytidine and its derivatives
US20240262857A1 (en) * 2021-05-27 2024-08-08 Emory University Novel universal anti-rna virus agents
CN117642410A (zh) * 2021-06-18 2024-03-01 苏州春海生物医药有限公司 N4-羟基胞苷的酯衍生物及其用途
CN113321694A (zh) * 2021-06-22 2021-08-31 药康众拓(江苏)医药科技有限公司 N4-羟基胞苷衍生物及其制备方法和用途
CN113735929A (zh) * 2021-07-21 2021-12-03 海化生命(厦门)科技有限公司 一种抗冠状病毒的化合物及其制备方法与应用
CA3226836A1 (en) 2021-08-06 2023-02-09 Intervet International B.V. Method of treating veterinary viral diseases
WO2023025319A1 (zh) * 2021-08-27 2023-03-02 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
CN113980074A (zh) * 2021-10-21 2022-01-28 苏州立新制药有限公司 N4-羟基胞苷的晶型a与制备方法和用途
US20250032527A1 (en) 2021-11-01 2025-01-30 Immunic Ag Medical use of n4-hydroxy citicoline compounds
KR20240110012A (ko) * 2021-11-12 2024-07-12 수저우 스프링-씨 바이오-파머수티컬 코., 엘티디. N4-하이드록시시티딘의 에스테르 유도체 및 이의 용도
US11541071B1 (en) 2021-12-16 2023-01-03 Ascletis BioScience Co., Ltd Nucleoside derivatives and methods of use thereof
CN116496334A (zh) * 2022-01-25 2023-07-28 上海和誉生物医药科技有限公司 一种抗病毒抑制剂及其在药学上的应用
CN116554249B (zh) * 2022-01-28 2025-03-18 北京恩泰伟医药科技有限公司 抗病毒化合物及其用途
WO2023161427A1 (en) 2022-02-24 2023-08-31 Eisbach Bio Gmbh Viral combination therapy
WO2023167488A1 (ko) * 2022-03-02 2023-09-07 유재혁 몰누피라비르의 국소 투여용 수의학적 조성물 및 그 이용
KR102917091B1 (ko) * 2022-03-02 2026-01-23 유재혁 몰누피라비르의 국소 투여용 수의학적 조성물 및 그 이용
CN116731087A (zh) * 2022-03-03 2023-09-12 上海科胜药物研发有限公司 一种莫那比拉韦及其中间体的制备方法
KR20230130898A (ko) * 2022-03-04 2023-09-12 동아대학교 산학협력단 N4-이소부티릴옥시시티딘 모방체 합성과 이의 항바이러스 용도를 포함하는 바이러스 감염 치료용 조성물
CN114573651A (zh) * 2022-03-11 2022-06-03 山东大学 一种n4-羟基胞苷脂质前药及其制备方法与应用
IL315480A (en) 2022-03-15 2024-11-01 Rome Therapeutics Inc Compounds and methods for treating disease
CN114805458B (zh) * 2022-03-31 2023-09-08 中国人民解放军军事科学院军事医学研究院 类核苷广谱抗病毒药物的脂肪酸前药及其制备方法和用途
CN116589518B (zh) * 2022-06-10 2026-04-28 南京知和医药科技有限公司 一种新型的胞苷衍生物及其药物组合物和用途
CN117586330A (zh) * 2022-08-12 2024-02-23 南京知和医药科技有限公司 一种新型核苷衍生物及其药物组合物和用途
WO2024123207A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации 5'-о-(3-фенилпропионил)-n4-гидроксицитидин и его применение
WO2024123206A1 (ru) * 2022-12-08 2024-06-13 федеральное государственное бюджетное учреждение "Национальный исследовательский центр эпидемиологии и микробиологии имени почетного академика Н.Ф. Гамалеи" Министерства здравоохранения Российской Федерации Способ получения 5',-о-(3-фенилпропионил)-n4-гидроксицитидина

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533406A (ja) 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
RU2264409C2 (ru) 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург
JP2012527477A (ja) 2009-05-20 2012-11-08 ギリアド ファーマセット エルエルシー Ｎ−［（２’ｒ）−２’−デオキシ−２’−フルオロ−２’−メチル−ｐ−フェニル−５’−ウリジリル］−ｌ−アラニン１−メチルエチルエステルおよびその製造のためのプロセス
WO2014070771A1 (en) 2012-10-29 2014-05-08 Rfs Pharma, Llc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
JP2014526516A (ja) 2011-09-16 2014-10-06 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv

Family Cites Families (276)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1325798A (en) 1970-09-24 1973-08-08 Upjohn Co Derivatives of 2,2-anhydro-ara-cytidine
GB1386334A (en) 1972-09-22 1975-03-05 Kohjin Co 2,2-cyclocytidine derivatives
GB1480120A (en) 1973-11-29 1977-07-20 Kohjin Co N4-substituted-2,2'-cyclocytidine derivatives
US4096324A (en) 1975-07-07 1978-06-20 The Upjohn Company Cytidine nucleoside compound
US5736531A (en) 1987-10-28 1998-04-07 Pro-Neuron, Inc. Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5470838A (en) 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
EP0476071A4 (en) 1989-06-05 1992-11-04 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides and methods for preparing the same
WO1992009705A1 (en) 1990-11-23 1992-06-11 Gilead Sciences, Inc. Triplex-forming oligomers containing modified bases
FI105556B (fi) * 1991-09-30 2000-09-15 Sankyo Co Menetelmä lääkeaineina käyttökelpoisten pyrimidiiniukleosidijohdannaisten valmistamiseksi, joilla on kasvaimen vastaista vaikutusta
AU3222793A (en) 1991-11-26 1993-06-28 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
EP0695306A1 (en) 1993-04-19 1996-02-07 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5349947A (en) * 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
CA2171868A1 (en) 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
CN100409844C (zh) 1995-02-27 2008-08-13 吉里德科学公司 神经氨酸苷酶抑制剂
US6043358A (en) 1995-11-01 2000-03-28 Merck & Co., Inc. Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases
WO1998017647A1 (en) 1996-10-21 1998-04-30 Gilead Sciences, Inc. Piperidine compounds
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6086376A (en) * 1998-01-30 2000-07-11 Rtp Pharma Inc. Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
FR2776289B1 (fr) 1998-03-20 2001-02-02 Oreal Composition de teinture d'oxydation contenant un coupleur cationique, procedes de teinture, nouveaux coupleurs cationiques
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US20030008841A1 (en) 2000-08-30 2003-01-09 Rene Devos Anti-HCV nucleoside derivatives
EP2180064A3 (en) 2000-10-18 2010-08-11 Pharmasset, Inc. Multiplex quantification of nucleic acids in diseased cells
CA2743451A1 (en) 2000-10-18 2002-04-25 Pharmasset, Inc. Modified nucleosides for the treatment of viral infections and abnormal cellular proliferation
PT1390378E (pt) 2001-04-30 2009-07-23 Trommsdorff Arzneimittel Ésteres de uridina farmaceuticamente activos
GB0114286D0 (en) 2001-06-12 2001-08-01 Hoffmann La Roche Nucleoside Derivatives
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
WO2003091264A2 (en) 2002-04-26 2003-11-06 Gilead Sciences, Inc. Non nucleoside reverse transcriptase inhibitors
US20050239054A1 (en) 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
AU2003253888A1 (en) 2002-07-15 2004-02-02 Gilead Sciences, Inc. Combination therapies with l-fmau for the treatment of hepatitis b virus infection
WO2004024185A1 (ja) 2002-09-11 2004-03-25 Michio Ishibashi 医薬または化粧料
AU2003279103A1 (en) 2002-10-01 2004-04-23 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
WO2004035577A2 (en) 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
WO2004043884A2 (en) * 2002-11-12 2004-05-27 Enzon Pharmaceuticals, Inc. Novel acylating reagents
TWI332507B (en) 2002-11-19 2010-11-01 Hoffmann La Roche Antiviral nucleoside derivatives
EP1581496A4 (en) 2002-12-02 2008-04-23 Gilead Sciences Inc 2-SUBSTITUTED 3-PROPENAMIDE DERIVATIVES AND PROCESS FOR THEIR PREPARATION
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
WO2005002626A2 (en) 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
MXPA05011294A (es) 2003-04-25 2006-03-15 Gilead Sciences Inc Compuestos de fosfonato anti-inflamatorios.
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
CN101410120A (zh) 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7427636B2 (en) 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US20060252729A1 (en) 2003-07-30 2006-11-09 Krawczyk Steven H Nucleobase phosphonate analogs for antiviral treatment
CA2537325A1 (en) 2003-09-19 2005-03-31 Gilead Sciences, Inc. Aza-quinolinol phosphonate integrase inhibitor compounds
WO2005042773A1 (en) 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
JP2007509994A (ja) 2003-11-03 2007-04-19 コグニス・アイピー・マネージメント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング アシルリボヌクレオシドおよびアシルデオキシリボヌクレオシド
BRPI0417988A (pt) 2003-12-22 2007-04-27 Gilead Sciences Inc análogos de fosfonato antivirais
EP2161273B1 (en) 2003-12-22 2015-04-15 K.U.Leuven Research & Development Imidazo[4,5-c]pyridine compounds and methods of antiviral treatment
ATE478082T1 (de) 2003-12-30 2010-09-15 Gilead Sciences Inc Phosphonate, monophosphonamidate, bisphosphonamidate zur behandlung von virenerkrankungen
CN1934093A (zh) 2004-01-12 2007-03-21 吉里德科学公司 嘧啶基膦酸酯抗病毒化合物和使用方法
US20070281911A1 (en) 2004-01-21 2007-12-06 Gilead Sciences Inc. Use of Adefovir or Tenofovir for Inhibiting Mmtv-Like Viruses Involved in Breast Cancer and Primary Biliary Cirrhosis
WO2005117904A2 (en) 2004-04-14 2005-12-15 Gilead Sciences, Inc. Phosphonate analogs of hiv integrase inhibitor compounds
UA93354C2 (ru) 2004-07-09 2011-02-10 Гилиад Сайенсиз, Инк. Местный противовирусный препарат
RS51974B (sr) 2004-07-16 2012-02-29 Gilead Sciences Inc. Antivirusna jedinjenja
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
BRPI0513811A (pt) 2004-07-27 2008-07-15 Gilead Sciences Inc imidazo [4,5-d] pirimidinas, seus usos e processos de preparação
DE102004051804A1 (de) 2004-10-21 2006-04-27 Max-Delbrück-Centrum Für Molekulare Medizin (Mdc) Beta-L-N4-Hydroxycytosin-Desoxynucleoside und ihre Verwendung als pharmazeutische Mittel zur Prophylaxe oder Therapie von viralen Erkrankungen
AU2005299284A1 (en) 2004-10-26 2006-05-04 Gilead Sciences, Inc. Phosphonate derivatives of mycophenolic acid
NZ556624A (en) 2004-12-21 2010-06-25 Gilead Sciences Inc 5-((3-(2,4-trifluoromethyphenyl)isoxazol-5-yl)methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine and method of antiviral treatment
WO2006091905A1 (en) 2005-02-25 2006-08-31 Gilead Sciences, Inc. Bicyclo (3.1.0) hexane derivatives as antiviral compounds
AR057023A1 (es) 2005-05-16 2007-11-14 Gilead Sciences Inc Compuestos heterociclicos con propiedades inhibidoras de hiv-integrasa
ES2569881T3 (es) 2005-06-08 2016-05-12 The University Of North Carolina At Chapel Hill Procedimientos para facilitar la supervivencia de células neuronales usando miméticos de neurotrofina BDNF peptídicos y no peptídicos
TW200738742A (en) 2005-07-14 2007-10-16 Gilead Sciences Inc Antiviral compounds
TWI389908B (zh) 2005-07-14 2013-03-21 Gilead Sciences Inc 抗病毒化合物類
US20070128625A1 (en) 2005-07-25 2007-06-07 Gilead Sciences, Llc Drug-resistant mutants of hepatitis C virus
EP1906971A2 (en) 2005-07-27 2008-04-09 Gilead Sciences, Inc. Antiviral compounds
US7589101B2 (en) 2005-08-16 2009-09-15 Irm Llc Compounds and compositions as protein kinase inhibitors
DE602006003913D1 (de) 2005-09-22 2009-01-08 Hoffmann La Roche Selektive o-acylierung von nukleosiden
EP1976517A1 (en) 2005-12-30 2008-10-08 Gilead Sciences, Inc. Methods for improving the pharmacokinetics of hiv integrase inhibitors
HRP20080554B1 (hr) 2006-03-29 2014-11-21 Gilead Sciences, Inc. Postupak priprave inhibitora proteaze hiv
WO2008003149A2 (en) 2006-07-06 2008-01-10 Gilead Sciences , Inc. Substituted pteridines for the treatment and prevention of viral infections
KR101143596B1 (ko) 2006-07-07 2012-05-11 길리애드 사이언시즈, 인코포레이티드 신규의 피리다진 화합물 및 이의 용도
US20080008682A1 (en) 2006-07-07 2008-01-10 Chong Lee S Modulators of toll-like receptor 7
PL2049506T5 (pl) 2006-07-07 2024-09-09 Gilead Sciences, Inc. Modulatory farmakokinetycznych właściwości leków
US7842672B2 (en) 2006-07-07 2010-11-30 Gilead Sciences, Inc. Phosphonate inhibitors of HCV
US10144736B2 (en) 2006-07-20 2018-12-04 Gilead Sciences, Inc. Substituted pteridines useful for the treatment and prevention of viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
US8338435B2 (en) 2006-07-20 2012-12-25 Gilead Sciences, Inc. Substituted pyrido(3,2-D) pyrimidines and pharmaceutical compositions for treating viral infections
WO2008009077A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
PT2069303E (pt) 2006-07-21 2016-06-08 Gilead Sciences Inc Inibidores de protease antiviral
WO2008011116A2 (en) 2006-07-21 2008-01-24 Gilead Sciences, Inc. Aza-peptide protease inhibitors
KR20110089463A (ko) 2006-07-24 2011-08-08 한국화학연구원 신규 ｈｉｖ 역전사 효소 억제제
WO2008013834A1 (en) 2006-07-24 2008-01-31 Gilead Sciences, Inc., Bisfuranyl protease inhibitors
MX2009003403A (es) 2006-09-27 2009-04-09 Coley Pharm Group Inc Composiciones de ligandos de tlr y antivirales.
WO2008133669A2 (en) 2006-12-14 2008-11-06 Gilead Sciences, Inc. Viral inhibitors
WO2008077649A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infectons
WO2008077650A1 (en) 2006-12-26 2008-07-03 Gilead Sciences, Inc. Pyrido(3,2-d)pyrimidines useful for treating viral infections
TW200840584A (en) 2006-12-26 2008-10-16 Gilead Sciences Inc Pyrido(3,2-d)pyrimidines useful for treating viral infections
WO2008100447A2 (en) 2007-02-09 2008-08-21 Gilead Sciences, Inc. Nucleoside analogs for antiviral treatment
MX2009008935A (es) 2007-02-23 2009-11-02 Gilead Sciences Inc Moduladores de las propiedades farmacocineticas de productos terapeuticos.
WO2008119659A2 (en) 2007-03-29 2008-10-09 F. Hoffmann-La Roche Ag Pharmaceutical composition and process
US20100331331A1 (en) 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
WO2009005677A2 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Antiviral compounds
AR067180A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Compuestos antivirales
AR067184A1 (es) 2007-06-29 2009-09-30 Gilead Sciences Inc Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
WO2009005693A1 (en) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Novel hiv reverse transcriptase inhibitors
EA019749B1 (ru) 2007-06-29 2014-06-30 Джилид Сайэнс, Инк. Противовирусные соединения
CA2691444C (en) 2007-06-29 2016-06-14 Gilead Sciences, Inc. Purine derivatives and their use as modulators of toll-like receptor 7
ES2533863T3 (es) 2007-06-29 2015-04-15 Korea Research Institute Of Chemical Technology Inhibidores novedosos de la transcriptasa inversa de VIH
UA99466C2 (en) 2007-07-06 2012-08-27 Гилиад Сайенсиз, Инк. Crystalline pyridazine compound
WO2009042767A1 (en) * 2007-09-26 2009-04-02 Mount Sinai School Of Medicine Azacytidine analogues and uses thereof
WO2009058800A2 (en) 2007-10-29 2009-05-07 President And Fellows Of Harvard College Synthesis of nucleosides
EP2234623A4 (en) * 2007-12-27 2012-03-28 Epiphany Biosciences ANTIVIRAL CONNECTIONS
US8759379B2 (en) 2008-01-04 2014-06-24 Gilead Sciences, Inc. Inhibitors of cytochrome P450
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
HUE025528T2 (en) 2008-04-23 2016-05-30 Gilead Sciences Inc 1'-substituted carba-nucleoside analogs for antiviral treatment
WO2009143011A1 (en) * 2008-05-20 2009-11-26 Novartis Ag Antiviral compositions, methods of making and using such compositions, and systems for pulmonary delivery of such compositions
WO2010002998A1 (en) 2008-07-03 2010-01-07 Gilead Sciences, Inc. 2,4,6-TRISUBSTITUTED PYRIDO (3,2-d) PYRIMIDINES USEFUL FOR TREATING VIRAL INFECTIONS
US8658617B2 (en) 2008-07-08 2014-02-25 Gilead Sciences, Inc. Salts of HIV inhibitor compounds
AR072534A1 (es) 2008-07-25 2010-09-01 Gilead Sciences Inc Compuestos antivirales
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
CN102300871A (zh) 2008-12-19 2011-12-28 吉里德科学公司 Hcv ns3蛋白酶抑制剂
CA2746834A1 (en) 2008-12-22 2010-07-01 Gilead Sciences, Inc. Antiviral compounds
MX2011008409A (es) 2009-02-10 2011-10-21 Gilead Sciences Inc Análogos de carba-nucléosido para tratamiento antiviral.
HUE030465T2 (hu) 2009-05-13 2017-05-29 Antivirális vegyületek
US20100324060A1 (en) 2009-06-23 2010-12-23 Gilead Sciences, Inc. Pharmaceutical compositions useful for treating hcv
AR077125A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Combinaciones farmaceuticas utiles para tratar el vhc
AR077138A1 (es) 2009-06-23 2011-08-03 Gilead Sciences Inc Composiciones farmaceuticas utiles para tratar el vhc
WO2011005842A1 (en) 2009-07-09 2011-01-13 Gilead Sciences, Inc. Anti-rsv compounds
AU2010276441B2 (en) 2009-07-21 2015-07-02 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
WO2011031669A1 (en) 2009-09-09 2011-03-17 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
CA2772253C (en) 2009-09-14 2018-02-27 Gilead Sciences, Inc. Modulators of toll-like receptors
US7973013B2 (en) 2009-09-21 2011-07-05 Gilead Sciences, Inc. 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment
CN102596958A (zh) 2009-09-21 2012-07-18 吉里德科学公司 用于抗病毒治疗的2’-氟代carba-核苷类似物
JP5694345B2 (ja) 2009-10-22 2015-04-01 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体の調節因子
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
MX2012008211A (es) 2010-01-15 2012-08-08 Gilead Sciences Inc Inhibidores de virus flaviviridae.
US8524764B2 (en) 2010-01-15 2013-09-03 Gilead Sciences, Inc. Inhibitors of Flaviviridae viruses
WO2011092158A1 (en) 2010-01-28 2011-08-04 F. Hoffmann-La Roche Ag 4 ' - azido - nucleosides as anti - hcv compunds
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
WO2011121453A2 (en) * 2010-03-30 2011-10-06 Clavis Pharma Asa Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
CA2796826A1 (en) 2010-05-10 2011-11-17 Gilead Sciences, Inc. Bifunctional quinoline derivatives
UY33373A (es) 2010-05-10 2011-12-30 Gilead Sciences Inc ?Compuestos de pirazolopiridina bifuncionales, su uso en terapia y composiciones que los comprenden?.
EP2571882A1 (en) 2010-05-21 2013-03-27 Gilead Sciences, Inc. Heterocyclic flaviviridae virus inhibitors
TW201201815A (en) 2010-05-28 2012-01-16 Gilead Sciences Inc 1'-substituted-carba-nucleoside prodrugs for antiviral treatment
TW201210597A (en) 2010-06-09 2012-03-16 Gilead Sciences Inc Inhibitors of hepatitis C virus
WO2011156757A1 (en) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combination of anti-hcv compounds with ribavirin for the treatment of hcv
CN103079561B (zh) 2010-06-11 2015-12-02 吉里德科学公司 用于预防hsv-2传播的局部用抗病毒制剂
CA2797926C (en) * 2010-06-16 2019-04-09 Clavis Pharma Asa Anti-human equilibrative nucleoside transporter 1 (hent1) antibodies and methods of use thereof
PT3012258T (pt) 2010-06-24 2018-12-14 Gilead Sciences Inc Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral
EP2588455B1 (en) 2010-07-02 2018-04-04 Gilead Sciences, Inc. 2-quinolinyl-acetic acid derivatives as hiv antiviral compounds
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
AU2011282241B2 (en) 2010-07-19 2015-07-30 Gilead Sciences, Inc. Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
ES2524356T3 (es) 2010-07-22 2014-12-05 Gilead Sciences, Inc. Métodos y compuestos para tratar infecciones provocadas por virus Paramyxoviridae
CN102351931B (zh) 2010-09-07 2014-01-22 河南省科学院高新技术研究中心 嘧啶核苷衍生物、合成方法及其在制备抗肿瘤、抗病毒药物中的应用
TW201305185A (zh) 2010-09-13 2013-02-01 吉李德科學股份有限公司 用於抗病毒治療之２’－氟取代之碳－核苷類似物
BR112013008017A2 (pt) 2010-09-20 2016-06-14 Gilead Sciences Inc análogos de carba-nucleosídeo 2-flúor substituídos para tratamento antiviral
NZ710567A (en) 2010-11-17 2017-01-27 Gilead Sciences Inc Antiviral compounds
JP2014500261A (ja) 2010-11-19 2014-01-09 ギリアード サイエンシーズ， インコーポレイテッド リルピビリンＨＣｌおよびフマル酸テノホビルジソプロキシルを含有する治療用組成物
PY1153144A (es) 2010-12-10 2015-01-01 Gilead Sciences Inc Inhibidores macrocíclicos de virus flaviviridae
US20130273005A1 (en) 2010-12-20 2013-10-17 Gilead Sciences, Inc. Methods for treating hcv
WO2012088156A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2012088153A1 (en) 2010-12-21 2012-06-28 Gilead Sciences, Inc. Inhibitors of cytochrome p450
US20130274254A1 (en) 2010-12-21 2013-10-17 Gilead Sciences, Inc. Inhibitors of cytochrome p450 (cyp3a4)
CA2830838A1 (en) 2011-04-04 2012-11-10 Gilead Sciences, Inc. Process for the preparation of an hiv integrase inhibitor
CA2830845A1 (en) 2011-04-04 2012-10-11 Gilead Sciences, Inc. Solid state forms of hiv inhibitor
US8877733B2 (en) 2011-04-13 2014-11-04 Gilead Sciences, Inc. 1′-substituted pyrimidine N-nucleoside analogs for antiviral treatment
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
AU2012250890B2 (en) 2011-05-02 2015-05-28 Gilead Sciences, Inc. Amorphous solid salts
JP2014522647A (ja) 2011-07-06 2014-09-08 ギリアード サイエンシーズ， インコーポレイテッド Ｈｃｖ遺伝子型４レプリコン
HK1197075A1 (en) 2011-07-06 2015-01-02 Gilead Sciences, Inc. Hcv genotype 3 replicons
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
PT2734515E (pt) 2011-07-13 2016-03-11 Gilead Sciences Inc Derivados de ácido tiofen-2-carboxílico úteis como inibidores de vírus flaviviridae
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
BR112014010295A2 (pt) 2011-10-31 2017-04-18 Gilead Pharmassett Llc métodos e composições para o tratamento de vírus de hepatite c
CN105837584B (zh) 2011-11-16 2018-07-13 吉利德制药有限责任公司 作为抗病毒化合物的缩合的咪唑基咪唑
JP5899327B2 (ja) 2011-11-29 2016-04-06 ギリアド ファーマセット エルエルシー Ｃ型肝炎ウイルスを処置するための組成物および方法
WO2013090840A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. 2 -amino- pyrido [3, 2 -d] pyrimidine derivatives as hcv inhibitors
WO2013090929A1 (en) 2011-12-15 2013-06-20 Gilead Sciences, Inc. Amino quinoline derivatives inhibitors of hcv
AU2012358994A1 (en) 2011-12-20 2014-08-07 Gilead Sciences, Inc. Pharmaceutical compositions and methods for treating gastrointestinal infections and disorders
JP6122868B2 (ja) 2011-12-22 2017-04-26 ギリアード サイエンシーズ， インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５−ａ］ピリミジン
SG10201913554YA (en) * 2011-12-22 2020-03-30 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9284323B2 (en) 2012-01-04 2016-03-15 Gilead Sciences, Inc. Naphthalene acetic acid derivatives against HIV infection
US9376392B2 (en) 2012-01-04 2016-06-28 Gilead Sciences, Inc. 2-(tert-butoxy)-2-(7-methylquinolin-6-yl) acetic acid derivatives for treating AIDS
CA2860995A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
AU2012327170A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
AU2013204727A1 (en) 2012-02-03 2013-08-22 Gilead Sciences, Inc. Therapeutic compounds
MD4496C1 (ro) 2012-03-13 2018-02-28 Gilead Sciences, Inc. Analogi carba-nucleozidici 2'-substituiţi pentru tratament antiviral
GEP201706721B (en) * 2012-03-21 2017-08-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
AU2013249280B2 (en) 2012-04-17 2017-10-12 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
US9079887B2 (en) 2012-05-16 2015-07-14 Gilead Sciences, Inc. Antiviral compounds
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
BR112014030649A2 (pt) 2012-06-08 2017-06-27 Gilead Sciences Inc inibidores macrocíclicos da flaviviridae vírus
AR091279A1 (es) 2012-06-08 2015-01-21 Gilead Sciences Inc Inhibidores macrociclicos de virus flaviviridae
PT2861604T (pt) 2012-06-08 2017-05-05 Gilead Sciences Inc Inibidores macrocíclicos de vírus flaviridae
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US8841340B2 (en) 2012-08-17 2014-09-23 Gilead Sciences, Inc. Solid forms of an antiviral compound
WO2014055618A1 (en) 2012-10-03 2014-04-10 Gilead Sciences, Inc. Solid state forms of hiv inhibitor: hemi-succinate of (2s)-2-tert-butoxy-2-(4-(2,3-dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methylquinolin-3-yl)acetic acid)
CN104755995B (zh) 2012-10-26 2017-10-24 皇家飞利浦有限公司 具有透明操作模式的自动立体显示设备
SG11201503065PA (en) 2012-10-30 2015-05-28 Gilead Sciences Inc Therapeutic and diagnostic methods related to lysyl oxidase-like 2 (loxl2)
US9353423B2 (en) 2012-11-07 2016-05-31 Gilead Sciences, Inc. HCV genotype 6 replicons
EP2935304A1 (en) 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
BR112015014457A2 (pt) 2012-12-21 2017-11-21 Alios Biopharma Inc composto ou sal farmaceuticamente aceitável do mesmo e composição farmacêutica e respectivos usos e processos para melhorar ou tratar infecção de hcv, para inibir a atividade da ns5b polimerase do vírus da hepatite c e a replicação de vírus da hepatite c
US9233974B2 (en) 2012-12-21 2016-01-12 Gilead Sciences, Inc. Antiviral compounds
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
US20140273023A1 (en) * 2013-03-15 2014-09-18 Saladax Biomedical Inc. Gemcitabine immunoassay
EP2981542B1 (en) 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
JP6366693B2 (ja) 2013-05-16 2018-08-01 リボサイエンス・エルエルシー ４’−フルオロ−２’−メチル置換ヌクレオシド誘導体
AU2014302711A1 (en) 2013-06-26 2015-12-10 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US20150072418A1 (en) 2013-08-16 2015-03-12 Gilead Sciences, Inc. Hcv genotype 4d replicons
LT3043803T (lt) 2013-09-11 2022-08-10 Emory University Nukleotidų ir nukleozidų kompozicijos ir jų panaudojimas
WO2015054465A1 (en) 2013-10-11 2015-04-16 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
UA119050C2 (uk) 2013-11-11 2019-04-25 Ґілеад Саєнсиз, Інк. ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ
WO2015084741A2 (en) 2013-12-02 2015-06-11 Gilead Pharmasset Llc Methods of treating hepatitis c virus infection in subjects with cirrhosis
JP6568541B2 (ja) 2013-12-23 2019-08-28 ギリアド ファーマセット エルエルシー 大環状ｈｃｖ ｎｓ３阻害トリペプチドの結晶形態
TW201609785A (zh) 2013-12-23 2016-03-16 吉李德製藥公司 固體型之抗病毒化合物
TWI660965B (zh) 2014-01-15 2019-06-01 美商基利科學股份有限公司 泰諾福韋之固體形式
US10441567B2 (en) 2014-01-17 2019-10-15 Ligand Pharmaceuticals Incorporated Methods and compositions for modulating hormone levels
WO2015120057A1 (en) 2014-02-05 2015-08-13 Gilead Sciences, Inc. Pharmaceutical combinations against co-infection with hiv and tuberculosis
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
WO2015130966A1 (en) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Antiviral agents
WO2015179448A1 (en) 2014-05-21 2015-11-26 Gilead Sciences, Inc. Therapeutic compounds
WO2015191526A2 (en) 2014-06-12 2015-12-17 Gilead Sciences, Inc. Antiviral compounds
AU2015274637B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274635B2 (en) 2014-06-13 2018-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
AU2015274626C1 (en) 2014-06-13 2018-08-09 Gilead Sciences, Inc. Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors
US10221197B2 (en) 2014-06-13 2019-03-05 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
MA40059A (fr) 2014-06-13 2015-12-17 Gilead Sciences Inc Inhibiteurs de la phosphatidylinositol 3-kinase
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
MA40031A (fr) 2014-06-24 2015-12-30 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
CN105288635A (zh) 2014-06-26 2016-02-03 昆明积大制药股份有限公司 一种含有阿糖胞苷5’-0-氨基酸酯的药物组合物
JP6522732B2 (ja) 2014-07-11 2019-05-29 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖを治療するためのトール様受容体の調節因子
TWI678369B (zh) 2014-07-28 2019-12-01 美商基利科學股份有限公司 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類
TWI673283B (zh) 2014-08-21 2019-10-01 美商基利科學股份有限公司 ２’－氯胺基嘧啶酮及嘧啶二酮核苷類
EP3186239B1 (en) 2014-08-29 2018-10-10 Gilead Sciences, Inc. Antiretroviral agents
WO2016036759A1 (en) 2014-09-04 2016-03-10 Gilead Sciences, Inc. Methods of treating or preventing hiv in patients using a combination of tenofovir alafenamide and dolutegravir
EP3034499A1 (en) 2014-12-17 2016-06-22 Gilead Sciences, Inc. Novel FXR (NR1H4) modulating compounds
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
JP7381190B2 (ja) 2014-12-26 2023-11-15 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
WO2016134054A1 (en) 2015-02-18 2016-08-25 Abbvie Inc. Anti-viral compounds
US9670205B2 (en) 2015-03-04 2017-06-06 Gilead Sciences, Inc. Toll like receptor modulator compounds
KR20190057158A (ko) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도
US20160303095A1 (en) 2015-04-14 2016-10-20 Gilead Sciences, Inc. Methods of treating hepatitis b virus
CN107849024A (zh) 2015-05-15 2018-03-27 吉利德科学公司 具有作为吲哚胺2,3‑二加氧酶抑制剂活性的苯并咪唑和咪唑并吡啶亚氨代甲酰胺化合物
EP4092037A1 (en) 2015-06-17 2022-11-23 Gilead Sciences, Inc. Co-crystals, salts and solid forms of tenofovir alafenamide
PT4070788T (pt) 2015-06-30 2023-06-06 Gilead Sciences Inc Formulações farmacêuticas
CA2921336A1 (en) 2015-06-30 2016-12-30 Gilead Sciences, Inc. Pharmaceutical formulations
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
US20210292327A1 (en) 2015-08-26 2021-09-23 Gilead Sciences, Inc. Deuterated toll-like receptor modulators
WO2017040895A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
WO2017040896A1 (en) 2015-09-02 2017-03-09 Abbvie Inc. Anti-viral compounds
CA2997955A1 (en) 2015-09-15 2017-03-23 Gilead Sciences, Inc. Modulators of toll-like receptors for the treatment of hiv
DK3785717T3 (da) 2015-09-16 2022-03-21 Gilead Sciences Inc Fremgangsmåder til behandling af coronaviridae-infektioner
AU2016330895A1 (en) 2015-09-30 2018-05-10 Gilead Sciences, Inc. Compounds and combinations for the treatment of HIV
US20190054090A1 (en) 2015-10-01 2019-02-21 Gilead Sciences, Inc. Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers
WO2017083304A1 (en) 2015-11-09 2017-05-18 Gilead Sciences, Inc. Therapeutic compositions for treatment of human immunodeficiency virus
JP6732915B2 (ja) 2015-12-15 2020-07-29 ギリアード サイエンシーズ， インコーポレイテッド ヒト免疫不全ウイルス中和抗体
CU20180059A7 (es) 2015-12-17 2018-10-04 Gilead Sciences Inc Compuestos inhibidores de la quinasa de unión a tank
WO2017106710A1 (en) 2015-12-17 2017-06-22 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
US10874683B2 (en) * 2016-03-10 2020-12-29 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
WO2017165489A1 (en) 2016-03-23 2017-09-28 Emory University Antiviral agents for treating zika and dengue virus infections
RS60410B1 (sr) 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
WO2017184668A1 (en) 2016-04-20 2017-10-26 Gilead Sciences, Inc. Methods for treating flaviviridae virus infections
WO2017184670A2 (en) 2016-04-22 2017-10-26 Gilead Sciences, Inc. Methods for treating zika virus infections
EA201892375A1 (ru) 2016-05-27 2019-08-30 Джилид Сайэнс, Инк. Способы лечения инфекций, вызываемых вирусом гепатита b
BR102017010009A2 (pt) 2016-05-27 2017-12-12 Gilead Sciences, Inc. Compounds for the treatment of hepatitis b virus infection
EP3471738A4 (en) 2016-06-20 2020-01-01 Merck Sharp & Dohme Corp. CYCLIC PHOSPHONATE-SUBSTITUTED NUCLEOSIDE DERIVATIVES AND METHOD FOR USE THEREOF FOR TREATING VIRUS DISEASES
WO2017223268A1 (en) 2016-06-22 2017-12-28 Yale University COMPOSITIONS AND METHODS OF RESENSITIZING CELLS TO BROMODOMAIN AND EXTRATERMINAL DOMAIN PROTEIN INHIBITORS (BETi)
PT3706762T (pt) 2017-12-07 2024-12-05 Univ Emory N4-hidroxicitidina e derivados e utilizações antivirais relacionadas com os mesmos
KR20200140274A (ko) 2018-03-07 2020-12-15 에모리 유니버시티 4'-할로겐 함유 뉴클레오티드 및 뉴클레오시드 치료 조성물 및 이와 관련된 용도
WO2021159044A1 (en) * 2020-02-07 2021-08-12 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004533406A (ja) 2000-10-18 2004-11-04 フアーマセツト・リミテツド ウイルス感染症および異常細胞増殖を治療するための修飾ヌクレオシド
RU2264409C2 (ru) 2003-10-01 2005-11-20 Государственный научный центр вирусологии и биотехнологии "Вектор" (ГНЦ ВБ "Вектор") 2`-амино-2`-дезоксинуклеозиды - ингибиторы репродукции вирусов кори и марбург
JP2012527477A (ja) 2009-05-20 2012-11-08 ギリアド ファーマセット エルエルシー Ｎ−［（２’ｒ）−２’−デオキシ−２’−フルオロ−２’−メチル−ｐ−フェニル−５’−ウリジリル］−ｌ−アラニン１−メチルエチルエステルおよびその製造のためのプロセス
JP2014526516A (ja) 2011-09-16 2014-10-06 ギリアド ファーマセット エルエルシー Ｈｃｖを処置するための方法
WO2014070771A1 (en) 2012-10-29 2014-05-08 Rfs Pharma, Llc Pyrimidine nucleotides and their monophosphate prodrugs for treatment of viral infections and cancer
WO2014124430A1 (en) 2013-02-11 2014-08-14 Emory University Nucleotide and nucleoside therapeutic compositions and uses related thereto
WO2014169278A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Highly active nucleoside derivative for the treatment of hcv

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃａｌ Ｃｈｅｍｉｓｔｒｙ，２０１３，Ｖｏｌ．５６，ｐ．９４０３－９４１４

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023153865A (ja) * 2014-12-26 2023-10-18 エモリー・ユニバーシテイ Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途

Also Published As

Publication number Publication date
US20230293566A1 (en) 2023-09-21
WO2016106050A1 (en) 2016-06-30
IL279663B2 (en) 2023-02-01
US12551497B2 (en) 2026-02-17
SI3236972T1 (sl) 2021-12-31
IL279663B (en) 2022-10-01
AU2023270335B2 (en) 2025-09-11
EP3236972A4 (en) 2019-01-23
SMT202100592T1 (it) 2021-11-12
PL3236972T3 (pl) 2022-03-07
EP3939985A1 (en) 2022-01-19
EP3236972B1 (en) 2021-07-28
EP3939985B1 (en) 2024-05-08
AU2023270335A1 (en) 2023-12-14
DK3236972T3 (en) 2021-10-04
US11628181B2 (en) 2023-04-18
CN118286245A (zh) 2024-07-05
US20210060050A1 (en) 2021-03-04
CY1124663T1 (el) 2022-07-22
EA201791460A1 (ru) 2017-12-29
JP2022058363A (ja) 2022-04-12
PT3236972T (pt) 2021-09-24
IL296496A (en) 2022-11-01
RS62434B1 (sr) 2021-11-30
SG11201705069YA (en) 2017-07-28
HUE056470T2 (hu) 2022-02-28
JP2018500354A (ja) 2018-01-11
EP3236972A1 (en) 2017-11-01
ES2892123T3 (es) 2022-02-02
AU2021203840A1 (en) 2021-07-08
KR20170123308A (ko) 2017-11-07
IL296496B2 (en) 2024-10-01
KR20230130175A (ko) 2023-09-11
AU2021203840C1 (en) 2024-01-25
IL252997B (en) 2021-01-31
JP2025098020A (ja) 2025-07-01
AU2021203840B2 (en) 2023-08-24
HRP20211456T1 (hr) 2021-12-24
IL279663A (en) 2021-03-01
US20190022116A1 (en) 2019-01-24
AU2015370004B2 (en) 2021-03-11
IL296496B1 (en) 2024-06-01
SG10202105371YA (en) 2021-07-29
LT3236972T (lt) 2021-11-10
CN107427529A (zh) 2017-12-01
AU2015370004A1 (en) 2017-07-13
BR112017013858A2 (pt) 2018-02-27
IL252997A0 (en) 2017-08-31
JP2023153865A (ja) 2023-10-18
CA2972259A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
JP7381190B2 (ja) Ｎ４－ヒドロキシシチジン及び誘導体並びにそれに関連する抗ウイルス用途
JP7786743B2 (ja) ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
US10874683B2 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
KR102248165B1 (ko) N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
JP2026027247A (ja) ４’－ハロゲン含有ヌクレオチドおよびヌクレオシド治療組成物ならびにそれらに関連する使用
HK40062633A (en) Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
HK40062633B (en) Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
EA045500B1 (ru) Противовирусное применение производных n4-гидроксицитидина
BR122022008542B1 (pt) Uso de um composto e composição farmacêutica o compreendendo

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20191112

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200207

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201020

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210114

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210817

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211216

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211216

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220104

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220201

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220208

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20220304

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20220308

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230124

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20230418

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230425

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231102

R150 Certificate of patent or registration of utility model

Ref document number: 7381190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R157 Certificate of patent or utility model (correction)

Free format text: JAPANESE INTERMEDIATE CODE: R157

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350